REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…
Matched conditions: REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Antibody-Drug combo aims to tackle tough leukemia
Disease control Recruiting nowThis study is testing a drug called inotuzumab ozogamicin, which is like a smart bomb that targets and kills leukemia cells, combined with low-intensity chemotherapy. The goal is to find the best dose and see if this combo works better than standard treatments for patients with a…
Matched conditions: REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a pill make CAR T-Cell therapy last longer?
Disease control Recruiting nowThis early-phase trial tests whether the drug pomalidomide can improve the effects of CAR T-cell therapy in people with B-cell leukemias or lymphomas that have returned or not responded to treatment. The study will enroll 12 adults who have already received CAR T-cell therapy. Re…
Matched conditions: REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for kids with tough leukemia: targeted Antibody-Drug combo shows promise
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin in children and young adults (ages 1 to 21) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard treatment. The drug works like a guided missile, attaching to a marker (CD22) on cancer cel…
Matched conditions: REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Matched conditions: REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for hard-to-treat leukemia: triple drug combo enters human testing
Disease control Recruiting nowThis early-phase trial tests whether combining three drugs (recombinant Erwinia asparaginase, venetoclax, and blinatumomab) is safe and effective for adults whose B-cell acute lymphoblastic leukemia has returned or not responded to prior treatment. The study enrolls 26 people age…
Matched conditions: REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC